Catalent Biologics is adopting Berkeley Lights, Inc.’s Beacon optofluidic platform to accelerate its cell line development workflow.   The Beacon platform is capable of screening thousands of clones in parallel. According to the company, in five days, the top producing clones are identified and scale up can begin, expediting the development process. Automating the process on the Beacon platform aims to increase efficiencies, allow for faster identification of the top producing clones and provi...